EP0792157A4 - Herstellung von mhc-peptid-komplexen - Google Patents

Herstellung von mhc-peptid-komplexen

Info

Publication number
EP0792157A4
EP0792157A4 EP95938126A EP95938126A EP0792157A4 EP 0792157 A4 EP0792157 A4 EP 0792157A4 EP 95938126 A EP95938126 A EP 95938126A EP 95938126 A EP95938126 A EP 95938126A EP 0792157 A4 EP0792157 A4 EP 0792157A4
Authority
EP
European Patent Office
Prior art keywords
mhc
preparation
peptide complexes
complexes
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95938126A
Other languages
English (en)
French (fr)
Other versions
EP0792157A1 (de
Inventor
Bishwajit Nag
Jeffrey L Winkelhake
Prabha V Mukku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anergen Inc
Original Assignee
Anergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anergen Inc filed Critical Anergen Inc
Publication of EP0792157A1 publication Critical patent/EP0792157A1/de
Publication of EP0792157A4 publication Critical patent/EP0792157A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP95938126A 1994-09-30 1995-09-29 Herstellung von mhc-peptid-komplexen Withdrawn EP0792157A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31553994A 1994-09-30 1994-09-30
US315539 1994-09-30
PCT/US1995/012575 WO1996010415A1 (en) 1994-09-30 1995-09-29 Preparation of mhc-peptide complexes

Publications (2)

Publication Number Publication Date
EP0792157A1 EP0792157A1 (de) 1997-09-03
EP0792157A4 true EP0792157A4 (de) 1999-12-01

Family

ID=23224886

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95938126A Withdrawn EP0792157A4 (de) 1994-09-30 1995-09-29 Herstellung von mhc-peptid-komplexen

Country Status (6)

Country Link
EP (1) EP0792157A4 (de)
JP (1) JPH10509693A (de)
KR (1) KR970706014A (de)
AU (1) AU3887495A (de)
CA (1) CA2201519A1 (de)
WO (1) WO1996010415A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824315A (en) * 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
WO1996010415A1 (en) * 1994-09-30 1996-04-11 Anergen, Inc. Preparation of mhc-peptide complexes
US20050176070A1 (en) * 2001-04-05 2005-08-11 Auton Kevin A. Protein analysis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007707A1 (en) * 1993-09-14 1995-03-23 Cytel Corporation Alteration of immune response using pan dr-binding peptides
WO1996010415A1 (en) * 1994-09-30 1996-04-11 Anergen, Inc. Preparation of mhc-peptide complexes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130297A (en) * 1988-06-23 1992-07-14 Anergen, Inc. Conjugates useful in ameliorating autoimmunity MHC-II-peptide
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5468481A (en) * 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007707A1 (en) * 1993-09-14 1995-03-23 Cytel Corporation Alteration of immune response using pan dr-binding peptides
WO1996010415A1 (en) * 1994-09-30 1996-04-11 Anergen, Inc. Preparation of mhc-peptide complexes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9610415A1 *

Also Published As

Publication number Publication date
CA2201519A1 (en) 1996-04-11
AU3887495A (en) 1996-04-26
WO1996010415A1 (en) 1996-04-11
EP0792157A1 (de) 1997-09-03
KR970706014A (ko) 1997-11-03
JPH10509693A (ja) 1998-09-22

Similar Documents

Publication Publication Date Title
GB9420390D0 (en) Liposomal agents
IL118825A0 (en) 6-dimethylaminomethyl -1- phenyl-cyclohexane compounds their preparation and use
IL119864A0 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-OL compounds their preparation and use
PL311736A1 (en) Derivatives of 1h-imidazoles
GB9503240D0 (en) Preparation
EP0855914A4 (de) Stabile formulierungen des mhc-peptid-komplexes
PL321686A1 (en) Trensdermal preparation
IL116924A0 (en) Preparation of n-aryl- and n-hetarylhydroxylamines
GB9408053D0 (en) Pharmaceutical preparation
EP0699684A3 (de) Verfahren zur Herstellung von Alkalimetall-Hexamethyldisilazanen
GB9412350D0 (en) New compound and its preparation
EP0792157A4 (de) Herstellung von mhc-peptid-komplexen
EP0717985A4 (de) Dermatologische zubereitungen
EP0755671A4 (de) Dermatologisches präparat
NZ295530A (en) Preparation of 1-halo-3-trialkylsilanyl-benzenes
IL117786A (en) Preparation of alpha-bisoximes
ZA957201B (en) Liposome preparation
ZA955582B (en) Inclusion complexes of ranitidine
EP0790832A4 (de) Topische präparate
GB9414971D0 (en) Preparation of thionucleosides
HU9403029D0 (en) Praess for preparation of n-methoxy-acetyl-anilines
ZA952013B (en) Pharmaceutical preparation
PL303392A1 (en) Bituminating preparation
GB9405033D0 (en) Preparation
GB9418295D0 (en) Preparation of indoloquinone compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970423

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19991018

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010129

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031021